Zhang et al. assess TM6SF2's role in MASLD through gut-liver axis, highlighting microbiota implications.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) involve a complex interplay of genetics, metabolism, and the gut-liver axis. In a new study, Zhang et al. assess a previously unrecognized role of the intestinal epithelium in protecting against MASH by focusing on Transmembrane 6 Superfamily Member 2 (TM6SF2), a gene highly expressed in both the liver and intestine, whose common loss-of-function variant (E167K) is a well-established genetic risk factor for MASLD/MASH in humans. Herein, we provide an overview of Zhang et al.’s study and highlight the clinical significance of these new findings by focusing on two specific areas: the gut-liver axis in MASLD and the modification of the intestinal microbiota.
No takes yet. Share an insight, caveat, or question.
Kalligeros et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: